Work

KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

Year: 2015

Type: article

Abstract: The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the RAS-RAF-MEK-ERK (MAPK) pathway have resulted in enhanced understanding of the KRAS mutant NSCLC and have provided optimism that this disease can be targeted.

Source: Clinical and Translational Medicine

DOI: 10.1186/s40169-015-0075-0

Authors: Saveri Bhattacharya, Mark A. Socinski, Timothy F. Burns

Institution: UPMC Hillman Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,470